The diagnosis of polycythemia vera (PV) is currently based on clinical and biological criteria defined either by the World Health Organization (WHO) or the Polycythemia Vera Study Group (PVSG).
1,2 Both of these classifications use clinical and biological markers organized in major and minor criteria, allowing to diagnose a PV when a define combination of major and minor criteria is present. Recently, a somatic point mutation of the tyrosine kinase JAK2 (JAK2 V617F) has been described in about 80% of PV patients as well as 30% of essential thrombocythemia (ET) and 50% of idiopathic myelofibrosis (IMF) [3] [4] [5] [6] and several in vitro and in vivo experiments demonstrated that this mutation of JAK2 was the molecular event at the origin of PV. 3 It was therefore tempting to use the detection of JAK2V617F as a diagnostic test for erythrocytosis. Such an attitude supposes the development of other techniques than sequencing, as this latter is time consuming and not always feasible in hematology laboratories. We thus compared sequencing with two techniques of real-time PCR-based mutation detection (one using the LightCycler s instrument, the other the Taqman s ABI Prism 7500), for the efficiency to detect the JAK2 V617F mutation in 119 samples from patients with suspicion of myeloproliferative disorder (MPD). The three techniques were equivalent in all samples but one, where sequencing failed to detect the mutation revealed by both LightCycler s and Taqman s technologies. To evaluate the sensitivity of these techniques, we tested serial dilutions of the homozygously mutated HEL cell line DNA in the nonmutated TF-1 cell line DNA, and serial dilutions of the genomic DNA from a patient homozygous for the JAK2 V617F mutation in normal DNA. Sequencing failed to detect the mutated allele under 5% of HEL cell line DNA diluted in TF-1 cell line DNA, and under 10% of the homozygously mutated patient's DNA diluted in normal DNA. The sensitivity of LightCycler s and Taqman s techniques were equivalent, slightly higher than sequencing, reaching 0.5-1% of HEL cell line DNA diluted in TF-1 cell line DNA (Figure 1) , and 2-4% of a homozygously mutated patient's DNA diluted in normal DNA.
We then investigated in 88 patients with a newly diagnosed erythrocytosis if the detection of the mutation correlated with usual criteria of PV, as WHO and PVSG classifications, endogenous erythroid colonies (EEC) formation, and a low serum erythropoietin (Epo) level, thus facilitating the diagnosis of PV (Table 1) . We retained 51% for the upper end of the normal range for hematocrit value. 7 Clinical data were incomplete for seven patients, explaining why the diagnosis of PV could not be affirmed either with the WHO or with the PVSG criteria. Owing to the differences between the A1 criteria of both classifications, six patients who did not have any red cell mass measurement could be classified in the WHO and not in the PVSG classification. One patient had both an hypoxia and EEC formation, therefore making the diagnosis difficult. A cytogenetic analysis was performed in 35 patients; among 32 PV patients (according to the WHO criteria), seven had cytogenetic abnormalities: five with trisomy 9, one with 7q-, and one with additional material on chromosome 18.
JAK2 V617F was present in 43/45 (96%) patients diagnosed as PV according to the PVSG criteria and in 57/61 (93%) patients diagnosed with the WHO criteria (Table 1) . Nevertheless, 8/29 patients classified as non-PV according to the PVSG classification presented the mutation, whereas none of the 19 non-PV patients of the WHO; these eight patients were considered Table 1 Characteristics of patients WHO criteria PVSG criteria WHO and PVSG criteria It has been shown that Epo-dependant cell lines transfected with JAK2 V617F were independent as well as hypersensitive to Epo for their growth, thus mimicking the independence and hypersensibility of erythroid progenitors described in PV. [3] [4] [5] [6] Therefore, we hypothesized that the patients bearing JAK2 V617F also exhibited EEC formation. Among the 67 patients who had EEC, 62 harbored the JAK2 V617F mutation, five patients being nonmutated using sensitive techniques for the detection. Among these five patients, 4/5 and 2/5 could be classified in the PV group according to the WHO and the PVSG criteria, respectively. In total the presence or absence of the JAK2 V617F mutation correlated with the ability or the inability to form EEC in 81/87 patients (93.1%, R ¼ 0.824, Po0.0001). Finally, we compared the serum Epo level (either below or under the lower end of the normal range) with the presence or absence of V617F JAK2 and found that 52/68 patients (76%, R ¼ 0.416, P ¼ 0.0004) had an adequate correlation.
To study if the detection of JAK2 V617F could be performed, at the time of diagnosis, in peripheral blood granulocytes, thus avoiding a bone marrow aspirate, we studied 50 patients (including 35 PV, 8 SE, and eight other suspicions of MPD) whose both bone marrow and peripheral blood specimen were available. In all cases (34 mutated, 16 nonmutated), the mutation was identically detected.
Altogether, these data indicate that the JAK2 V617F mutation can be efficiently and easily detected by two sensitive techniques of SNP genotyping. Besides, this study confirmed that JAK2 V617F was not detected in any WHO-PV-negative patients, as already published by different teams, [3] [4] [5] [6] giving this parameter a 100% positive predictive value. This finding is the basis to look for the mutation in all patients with erythrocytosis, thus affirming the diagnosis of myeloproliferative disorder of PV type, if JAK2 V617F is present. We can thus propose a new diagnostic chart of PV where the detection of JAK2 V617F in granulocytes with sensitive techniques is the first step in the diagnosis of an erythrocytosis, except in the case of an obvious secondary erythrocytosis (Figure 2 ). This attitude has many advantages: it avoids realizing an isotopic red cell mass measurement, which is not always available and whose result is sometimes controversial. It can also avoid a bone marrow aspirate and EEC assays, which are time-consuming and not well Letter to the Editor above 51% and negative for JAK2 V617F should have all the investigations that are actually performed to characterize an erythrocytosis. Besides, the detection of the JAK2 V617F mutation can help make the diagnosis of PV, especially in the atypical cases of a hypoxia associated with an absolute erythrocytosis where the etiology of a secondary erythrocytosis is hardly eliminated. Even if the sole detection of JAK2 V617F in the context of erythrocytosis will assert the diagnosis of PV, the realization of a bone marrow biopsy can still be useful, as it can show signs of myelofibrosis, or the presence of blasts cells, therefore affirming the leukemic transformation of PV. Nevertheless, it seems to us that a bone marrow biopsy should be realized in the context of a prospective study, together with a cytogenetic analysis.
JAK2 V617F was also detected in 30% of ET, 50% of IMF, and some rare uncharacterized MPD, 8 therefore defining a new group of MPD with different clinical presentations. The reasons of these differences are still unknown and it is still too early to regroup these diseases in one unique myeloproliferative entity with a common physiopathological cause and different phenotypes. Prospective studies should characterize more accurately the common hallmarks between PV, ET, IMF and other rare MPDs that carry JAK2 V617F, especially in term of absolute erythrocytosis, Epo level, myelofibrosis, cytogenetic abnormalities and clinical outcome. It is thus conceivable that the detection of JAK2 V617F will be used as an initial tool in the diagnosis of chronic hyperleukocytosis, thrombocytosis and erythrocytosis. 
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Figure 2
Diagnostic chart proposed for the diagnosis of an erythrocytosis (i.e. hematocrit value above 51%). The number of patients concerned at each step of the chart is written next to each item (n), only the patients having had all clinical data being listed here (n ¼ 81). The detection of JAK2 V617F as a first intention diagnostic test would have avoided 58/81 patients to have other investigations to diagnose a myeloproliferative disorder of PV type.
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